Market Cap | 46.60M | P/E | - | EPS this Y | 28.70% | Ern Qtrly Grth | - |
Income | -22.27M | Forward P/E | -2.52 | EPS next Y | 3.30% | 50D Avg Chg | -17.00% |
Sales | 55.18k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -8.00% |
Dividend | N/A | Price/Book | 3.02 | EPS next 5Y | - | 52W High Chg | -39.00% |
Recommedations | 1.60 | Quick Ratio | 3.44 | Shares Outstanding | 16.22M | 52W Low Chg | 35.00% |
Insider Own | 16.45% | ROA | -65.14% | Shares Float | 14.26M | Beta | 0.43 |
Inst Own | 11.90% | ROE | -141.57% | Shares Shorted/Prior | 149.60K/156.67K | Price | 3.78 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 48,300 | Target Price | 8.80 |
Oper. Margin | -40,336.86% | Earnings Date | May 10 | Volume | 32,077 | Change | -5.03% |
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.
HC Wainwright & Co. | Buy | Apr 25, 24 |
Oppenheimer | Outperform | Apr 23, 24 |
HC Wainwright & Co. | Buy | Apr 1, 24 |
Chardan Capital | Buy | Mar 27, 24 |
HC Wainwright & Co. | Buy | Dec 4, 23 |
HC Wainwright & Co. | Buy | Sep 18, 23 |
Maxim Group | Buy | Sep 12, 23 |
HC Wainwright & Co. | Buy | Aug 31, 23 |
Chardan Capital | Buy | Aug 14, 23 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Calabrese Salvatore | CHIEF FINANCIAL OFFI.. CHIEF FINANCIAL OFFICER | May 19 | Buy | 8100 | 3,000 | 24,300,000 | 05/19/22 | |
RICHMAN ERIC I | Chief Executive Offi.. Chief Executive Officer | Aug 16 | Buy | 7.866 | 4,922 | 38,716 | 216,820 | 04/21/22 |